Pseudomonas aeruginosa is an opportunistic pathogen that can cause various life-threatening infections. Several unique characteristics make it the ability of survivability and adaptable and develop resistance to antimicrobial agents through multiple mechanisms. Heteroresistance, which is a subpopulation-mediated resistance, has received increasing attention in recent years. Heteroresistance may lead to unexpected treatment failure if not diagnosed in time and treated properly. Therefore, heteroresistant Pseudomonas aeruginosa infections pose considerable problems for hospital-acquired infections. However, the clinical prevalence and implications of Pseudomonas aeruginosa heteroresistance have not been reviewed.
Results:
In this work, the aspects of the clinically reported heteroresistance of Pseudomonas aeruginosa to commonly used antibiotic agents are reviewed. The prevalence, mechanisms, and clinical relevance of each reported heteroresistant Pseudomonas aeruginosa are discussed.
Get full access to this article
View all access options for this article.
References
1.
HurleyJC. Worldwide variation in Pseudomonas associated ventilator associated pneumonia. A meta-regression. J Crit Care, 2019; 51:88–93; doi: 10.1016/j.jcrc.2019.02.001
2.
HaghiF, ZeighamiH, MonazamiA, et al.Diversity of virulence genes in multidrug resistant Pseudomonas aeruginosa isolated from burn wound infections. Microb Pathog, 2018; 115:251–256; doi: 10.1016/j.micpath.2017.12.052
3.
MittalR, AggarwalS, SharmaS, et al.Urinary tract infections caused by Pseudomonas aeruginosa: A minireview. J Infect Public Health, 2009; 2(3):101–11; doi: 10.1016/j.jiph.2009.08.003
4.
MauriceNM, BediB, SadikotRT. Pseudomonas aeruginosa biofilms: Host response and clinical implications in lung infections. Am J Respir Cell Mol Biol, 2018; 58(4):428–439; doi: 10.1165/rcmb.2017-0321TR
5.
SchaeferP, BaughRF. Acute otitis externa: An update. Am Fam Physician, 2012; 86(11):1055–1061.
6.
CerioliM, BataillerC, ConradA, et al.Pseudomonas aeruginosa implant-associated bone and joint infections: Experience in a regional reference center in France. Front Med (Lausanne), 2020; 7:513242; doi: 10.3389/fmed.2020.513242
NguyenL, GarciaJ, GruenbergK, et al.Multidrug-resistant Pseudomonas infections: Hard to treat, but hope on the horizon?. Curr Infect Dis Rep, 2018; 20(8):23; doi: 10.1007/s11908-018-0629-6
10.
NeyestaniZ, EbrahimiSA, GhazaghiA, et al.Review of anti-bacterial activities of curcumin against Pseudomonas aeruginosa. Crit Rev Eukaryot Gene Expr, 2019; 29(5):377–385; doi: 10.1615/CritRevEukaryotGeneExpr.2019029088
11.
GrabeinB, GraningerW, Rodríguez BañoJ, et al.Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect, 2017; 23(6):363–372; doi: 10.1016/j.cmi.2016.12.005
12.
WilliamsPC. Potential of fosfomycin in treating multidrug-resistant infections in children. J Paediatr Child Health, 2020; 56(6):864–872; doi: 10.1111/jpc.14883
13.
FarhanSM, RaafatM, AbourehabMAS, et al.Effect of imipenem and amikacin combination against multi-drug resistant Pseudomonas aeruginosa. Antibiotics (Basel), 2021; 10(11):1429; doi: 10.3390/antibiotic agents10111429
14.
KarlowskyJA, LobSH, RaddatzJ, et al.In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes-study for monitoring antimicrobial resistance trends, United States 2015–2017. Clin Infect Dis, 2021; 72(12):2112–2120; doi: 10.1093/cid/ciaa381
15.
CDC. Antibiotic Resistance Threats in the United States, 2019, Atlanta, GA: U.S. Department of Health and Human Services, CDC, 2019; doi: 10.15620/cdc:82532
16.
BandVI, SatolaSW, SmithRD, et al.Colistin heteroresistance is largely undetected among carbapenem-resistant Enterobacterales in the United States. mBio, 2021; 12(1):e02881-20; doi: 10.1128/mBio.02881-20
17.
El-HalfawyOM, ValvanoMA. Antimicrobial heteroresistance: An emerging field in need of clarity. Clin Microbiol Rev, 2015; 28(1):191–207; doi: 10.1128/cmr.00058-14
18.
BandVI, WeissDS. Heteroresistance: A cause of unexplained antibiotic treatment failure?. PLoS Pathog, 2019; 15(6):e1007726; doi: 10.1371/journal.ppat.1007726
19.
BandVI, SatolaSW, BurdEM, et al.Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection. mBio, 2018; 9(2): e02448-17; doi: 10.1128/mBio.02448-17
20.
PereiraC, LarssonJ, HjortK, et al.The highly dynamic nature of bacterial heteroresistance impairs its clinical detection. Commun Biol, 2021; 4(1):521; doi: 10.1038/s42003-021-02052-x
21.
BandVI, CrispellEK, NapierBA, et al.Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae. Nat Microbiol, 2016; 1(6):16053; doi: 10.1038/nmicrobiol.2016.53
22.
TanCH, LiJ, NationRL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother, 2007; 51(9):3413–3415; doi: 10.1128/aac.01571-06
23.
NicoloffH, HjortK, LevinBR, et al.The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification. Nat Microbiol, 2019; 4(3):504–514; doi: 10.1038/s41564-018-0342-0
24.
ButinM, ClarisO, LaurentF. Clinical impact of vancomycin heteroresistance in staphylococcal strains involved in neonatal sepsis: Discussion of a case report. Arch Pediatr, 2019; 26(4):236–237; doi: 10.1016/j.arcped.2019.03.002
25.
WangY, HuYJ, AiXM, et al.Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China. Chin Med J (Engl), 2013; 126(3):505–509.
26.
IbrahimD, JabbourJF, KanjSS. Current choices of antibiotic treatment for Pseudomonas aeruginosa infections. Curr Opin Infect Dis, 2020; 33(6):464–473; doi: 10.1097/qco.0000000000000677
27.
PangZ, RaudonisR, GlickBR, et al.Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotech Adv, 2019; 37(1):177–192; doi: 10.1016/j.biotechadv.2018.11.013
28.
ChatterjeeM, AnjuCP, BiswasL, et al.Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options. Int J Med Microbiol, 2016; 306(1):48–58; doi: 10.1016/j.ijmm.2015.11.004
29.
SavoiaD. New perspectives in the management of Pseudomonas aeruginosa infections. Future Microbiol, 2014; 9(7):917–928; doi: 10.2217/fmb.14.42
30.
FothergillJL, WinstanleyC, JamesCE. Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. Expert Rev Anti Infect Ther, 2012; 10(2):219–235; doi: 10.1586/eri.11.168
31.
BotelhoJ, GrossoF, PeixeL. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms, epidemiology and evolution. Drug Resist Updat, 2019; 44:100640; doi: 10.1016/j.drup.2019.07.002
32.
BassettiM, VenaA, CroxattoA, et al.How to manage Pseudomonas aeruginosa infections. Drugs Context, 2018; 7:212527; doi: 10.7573/dic.212527
33.
Howard-AndersonJ, DavisM, PageAM, et al.Prevalence of colistin heteroresistance in carbapenem-resistant Pseudomonas aeruginosa and association with clinical outcomes in patients: an observational study. J Antimicrob Chemother, 2022; 77(3):793–798; doi: 10.1093/jac/dkab461
34.
BalabanNQ, HelaineS, LewisK, et al.Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol, 2019; 17(7):441–448; doi: 10.1038/s41579-019-0196-3
35.
Van den BerghB, FauvartM, MichielsJ. Formation, physiology, ecology, evolution and clinical importance of bacterial persisters. FEMS Microbiol Rev, 2017; 41(3):219–251; doi: 10.1093/femsre/fux001
36.
BraunerA, FridmanO, GefenO, et al.Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol, 2016; 14(5):320–330; doi: 10.1038/nrmicro.2016.34
37.
DewachterL, FauvartM, MichielsJ. Bacterial heterogeneity and antibiotic survival: Understanding and combatting persistence and heteroresistance. Mol Cell, 2019; 76(2):255–267; doi: 10.1016/j.molcel.2019.09.028
38.
da SilvaAEB, MartinsAF, NodariCS, et al.Carbapenem-heteroresistance among isolates of the Enterobacter cloacae complex: Is it a real concern?. Eur J Clin Microbiol Infect Dis, 2018; 37(1):185–186; doi: 10.1007/s10096-017-3138-x
39.
LandmanD, SalameraJ, QualeJ. Irreproducible and uninterpretable Polymyxin B MICs for Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol, 2013; 51(12):4106–4111; doi: 10.1128/jcm.02129-13
40.
OkadoJB, Avaca-CruscaJS, OliveiraAL, et al.Daptomycin and vancomycin heteroresistance revealed among CC5-SCCmecII MRSA clone and in vitro evaluation of treatment alternatives. J Glob Antimicrob Resist, 2018; 14:209–216; doi: 10.1016/j.jgar.2018.05.001
41.
PlipatN, LivniG, BertramH, et al.Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus. J Clin Microbiol, 2005; 43(5):2494–2496; doi: 10.1128/jcm.43.5.2494-2496.2005
42.
TatoM, MorosiniM, GarcíaL, et al.Carbapenem heteroresistance in VIM-1-producing Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing. J Clin Microbiol, 2010; 48(11):4089–4093; doi: 10.1128/jcm.01130-10
43.
PournarasS, KristoI, VrioniG, et al.Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae. J Clin Microbiol, 2010; 48(7):2601–2604; doi: 10.1128/jcm.02134-09
44.
SunJD, HuangSF, YangSS, et al.Impact of carbapenem heteroresistance among clinical isolates of invasive Escherichia coli in Chongqing, southwestern China. Clin Microbiol Infect, 2015; 21(5):469.e1–10; doi: 10.1016/j.cmi.2014.12.013
45.
JuhászE, IvánM, PintérE, et al.Colistin resistance among blood culture isolates at a tertiary care centre in Hungary. J Glob Antimicrob Resist, 2017; 11:167–170; doi: 10.1016/j.jgar.2017.08.002
46.
LiJ, RaynerCR, NationRL, et al.Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother, 2006; 50(9):2946–2950; doi: 10.1128/aac.00103-06
47.
RodriguezCH, BombicinoK, GranadosG, et al.Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis, 2009; 65(2):188–91; doi: 10.1016/j.diagmicrobio.2009.05.019
48.
PournarasS, IkonomidisA, MarkogiannakisA, et al.Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems. J Med Microbiol, 2007; 56(Pt 1):66–70; doi: 10.1099/jmm.0.46816-0
49.
HermesDM, Pormann PittC, LutzL, et al.Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa. J Med Microbiol, 2013; 62(Pt 8):1184–1189; doi: 10.1099/jmm.0.059220-0
50.
AnderssonDI, NicoloffH, HjortK. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol, 2019; 17(8):479–496; doi: 10.1038/s41579-019-0218-1
51.
MascellinoMT, PorowskaB, De AngelisM, et al.Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug design, development and therapy, 2017; 11:2209–2220; doi: 10.2147/dddt.s136240
52.
El-HalfawyOM, ValvanoMA. Chemical communication of antibiotic resistance by a highly resistant subpopulation of bacterial cells. PLoS One, 2013; 8(7):e68874; doi: 10.1371/journal.pone.0068874
53.
EngelH, Gutiérrez-FernándezJ, FlückigerC, et al.Heteroresistance to fosfomycin is predominant in Streptococcus pneumoniae and depends on the murA1 gene. Antimicrob Agents Chemother, 2013; 57(6):2801–2808; doi: 10.1128/aac.00223-13
54.
WoottonM, HoweRA, HillmanR, et al.A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother, 2001; 47(4):399–403; doi: 10.1093/jac/47.4.399
55.
FinkSL, MartinelloRA, CampbellSM, et al.Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans. Antimicrob Agents Chemother, 2012; 56(1):582–583; doi: 10.1128/aac.05024-11
56.
NorazahA, LawNL, KamelAG, et al.The presence of heterogeneous vancomycin-lntermediate Staphylococcus aureus (heteroVISA) in a major Malaysian hospital. Med J Malaysia, 2012; 67(3):269–273.
57.
HiramatsuK, AritakaN, HanakiH, et al.Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet, 1997; 350(9092):1670–1673; doi: 10.1016/s0140-6736(97)07324-8
58.
PfeltzRF, SchmidtJL, WilkinsonBJ. A microdilution plating method for population analysis of antibiotic-resistant staphylococci. Microb Drug Resist, 2001; 7(3):289–295; doi: 10.1089/10766290152652846
59.
ShenX, HoCM, WongTS. Minimal size of coffee ring structure. J Phys Chem B, 2010; 114(16):5269–5274; doi: 10.1021/jp912190v
60.
van HalSJ, WehrhahnMC, BarbagiannakosT, et al.Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol, 2011; 49(4):1489–1494; doi: 10.1128/jcm.02302-10
61.
RiedererK, ShemesS, ChaseP, et al.Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: Comparison of Etest and Agar screening methods. J Clin Microbiol, 2011; 49(6):2147–2150; doi: 10.1128/jcm.01435-10
62.
LeonardSN, RossiKL, NewtonKL, et al.Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother, 2009; 63(3):489–492; doi: 10.1093/jac/dkn520
63.
SeoJ, WiYM, KimJM, et al.Detection of colistin-resistant populations prior to antibiotic exposure in KPC-2-producing Klebsiella pneumoniae clinical isolates. J Microbiol, 2021; 59(6):590–597; doi: 10.1007/s12275-021-0610-1
64.
Stojowska-SwędrzyńskaK, ŁupkowskaA, Kuczyńska-WiśnikD, et al.Antibiotic heteroresistance in Klebsiella pneumoniae. Int J Mol Sci, 2021; 23(1):449; doi: 10.3390/ijms23010449
65.
Lo-Ten-FoeJR, de SmetAM, DiederenBM, et al.Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob Agents Chemother, 2007; 51(10):3726–3730; doi: 10.1128/aac.01406-06
66.
LiuY, LiJ, DuJ, et al.Accurate assessment of antibiotic susceptibility and screening resistant strains of a bacterial population by linear gradient plate. Sci China Life Sci, 2011; 54(10):953–960; doi: 10.1007/s11427-011-4230-6
67.
ChackoKI, SullivanMJ, BeckfordC, et al.Genetic basis of emerging vancomycin, linezolid, and daptomycin heteroresistance in a case of persistent Enterococcus faecium bacteremia. Antimicrob Agents Chemother, 2018; 62(4): e02007-17; doi: 10.1128/aac.02007-17
68.
SunL, TalaricoS, YaoL, et al.Droplet digital PCR-based detection of clarithromycin resistance in Helicobacter pylori isolates reveals frequent heteroresistance. J Clin Microbiol, 2018; 56(9): e00019-18; doi: 10.1128/jcm.00019-18
69.
Ben MansourK, FendriC, BattikhH, et al.Multiple and mixed Helicobacter pylori infections: Comparison of two epidemiological situations in Tunisia and France. Infect Genet Evol, 2016; 37:43–48; doi: 10.1016/j.meegid.2015.10.028
70.
GuptaR, ThakurR, KushwahaS, et al.Isoniazid and rifampicin heteroresistant Mycobacterium tuberculosis isolated from tuberculous meningitis patients in India. Indian J Tuberc, 2018; 65(1):52–56; doi: 10.1016/j.ijtb.2017.08.005
71.
ChenJ, HuangF, YinX, et al.Assessments of different methods for testing heteroresistance to rifampicin in tubercle bacillus. J Nanosci Nanotech, 2018; 18(12):8414–8418; doi: 10.1166/jnn.2018.16377
72.
JarzembowskiT, WiśniewskaK, JóźwikA, et al.Heterogeneity of methicillin-resistant Staphylococcus aureus strains (MRSA) characterized by flow cytometry. Curr Microbiol, 2009; 59(1):78–80; doi: 10.1007/s00284-009-9395-x
73.
JiaX, MaW, HeJ, et al.Heteroresistance to cefepime in Pseudomonas aeruginosa bacteraemia. Int J Antimicrob Agents, 2020; 55(3):105832; doi: 10.1016/j.ijantimicag.2019.10.013
74.
HeJ, JiaX, YangS, et al.Heteroresistance to carbapenems in invasive Pseudomonas aeruginosa infections. Int J Antimicrob Agents, 2018; 51(3):413–421; doi: 10.1016/j.ijantimicag.2017.10.014
75.
MeiS, GaoY, ZhuC, et al.Research of the heteroresistance of Pseudomonas aeruginosa to imipenem. Int J Clin Exp Med, 2015; 8(4):6129–6132
76.
XuY, ZhengX, ZengW, et al.Mechanisms of heteroresistance and resistance to imipenem in Pseudomonas aeruginosa. Infect Drug Resist, 2020; 13:1419–1428; doi: 10.2147/idr.s249475
77.
OikonomouO, PanopoulouM, IkonomidisA. Investigation of carbapenem heteroresistance among different sequence types of Pseudomonas aeruginosa clinical isolates reveals further diversity. J Med Microbiol, 2011; 60(Pt 10):1556–1558; doi: 10.1099/jmm.0.032276-0
78.
PolliniS, FiscarelliE, MugnaioliC, et al.Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-β-lactamase-producing clone with a heterogeneous carbapenem resistance phenotype. Clin Microbiol Infect, 2011; 17(8):1272–1275; doi: 10.1111/j.1469-0691.2011.03466.x
79.
GaronzikSM, LiJ, ThamlikitkulV, et al.Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother, 2011; 55(7):3284–3294; doi: 10.1128/aac.01733-10
80.
PlachourasD, KarvanenM, FribergLE, et al.Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother, 2009; 53(8):3430–3436; doi: 10.1128/aac.01361-08
81.
LinJ, XuC, FangR, et al.Resistance and heteroresistance to colistin in Pseudomonas aeruginosa isolates from Wenzhou, China. Antimicrob Agents Chemother, 2019; 63(10):e00556-19; doi: 10.1128/aac.00556-19
82.
LyNS, BulittaJB, RaoGG, et al.Colistin and doripenem combinations against Pseudomonas aeruginosa: Profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother, 2015; 70(5):1434–1442; doi: 10.1093/jac/dku567
83.
PournarasS, IkonomidisA, NeouE, et al.Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam. J Antimicrob Chemother, 2008; 61(3):757–758; doi: 10.1093/jac/dkm528
84.
WalshCC, McIntoshMP, PelegAY, et al.In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother, 2015; 70(11):3042–3050; doi: 10.1093/jac/dkv221
85.
IkonomidisA, TsakrisA, KantzanouM, et al.Efflux system overexpression and decreased OprD contribute to the carbapenem heterogeneity in Pseudomonas aeruginosa. FEMS Microbiol Lett, 2008; 279(1):36–39; doi: 10.1111/j.1574-6968.2007.00997.x
86.
SchurekKN, SampaioJL, KifferCR, et al.Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother, 2009; 53(10):4345–4351; doi: 10.1128/aac.01267-08
87.
LeeJY, KoKS. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas aeruginosa clinical isolates. Diagn Microbiol Infect Dis, 2014; 78(3):271–276; doi: 10.1016/j.diagmicrobio.2013.11.027
88.
KhatibR, JoseJ, MustaA, et al.Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother, 2011; 66(7):1594–1599; doi: 10.1093/jac/dkr169
89.
LiuH, JiaX, ZouH, et al.Detection and characterization of tigecycline heteroresistance in E. cloacae: Clinical and microbiological findings. Emerg Microbes Infect, 2019; 8(1):564–574; doi: 10.1080/22221751.2019.1601031
